Whole exome sequencing (WES) is an effective technology in the pharmaceutical industry for identifying genetic variants in protein-coding areas. It assists in the study of disease processes, the identification of prospective therapeutic targets, and the prediction of patient responses. WES facilitates the development of precision medical techniques and guides individualized therapies, hence accelerating medication development.
A Snapshot on Whole Exome Sequencing (WES) Market
Whole exome sequencing is a typical next-generation sequencing (NGS) process that includes sequencing the genome's protein-coding regions. The human exome accounts for less than 2% of the genome but includes around 85% of known disease-related variations, making this technology a less expensive alternative to whole-genome sequencing.
Exome sequencing is often used to discover and characterize genetic variations that cause disorders such as Miller syndrome and Alzheimer's disease. It also offers a low-cost screening method for the detection of genetic diseases.
DataM Intelligence’s report on the whole exome sequencing market provides insightful analysis of the latest trends and developments in the market. It outlines the current market dynamics and provides detailed insights into the market growth, revenue opportunities, and key players. Our report provides an accurate assessment of the market size and opportunities and explores the potential impact of the latest trends and developments.
Driving Factors
The increased frequency of chronic and uncommon conditions, as well as the growing need for personalized therapy, next-generation sequencing, and genomics R&D (research and development), are important drivers driving market revenue growth.
All protein-coding sections of the genome are sequenced using a Next-Generation Sequencing (NGS) method known as entire exome sequencing, or exome sequencing. This approach is mostly used to search for and identify variations and mutations in any gene's protein-coding region throughout the whole genome.
Market Restraint
However, a lack of experienced specialists and a reliance on government funds are impeding the expansion of the whole-exome sequencing industry.
Competitive Landscape
The Global whole exome sequencing market is highly competitive with many players. Some of the prominent companies contributing to the market growth are:
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- Agilent Technologies Inc.
Curious about more insights on the Whole Exome Sequencing Market? Grab our Exclusive Sample Report
